Australia markets closed

Cynata Therapeutics Limited (CYP.XA)

Cboe AU - Cboe AU Real-time price. Currency in AUD
Add to watchlist
0.3150-0.0200 (-5.97%)
At close: 03:59PM AEST
Full screen
Previous close0.3350
Open0.3350
Bid0.3100 x N/A
Ask0.0000 x N/A
Day's range0.3100 - 0.3350
52-week range0.1000 - 0.3400
Volume58,449
Avg. volume32,037
Market capN/A
Beta (5Y monthly)0.92
PE ratio (TTM)N/A
EPS (TTM)-0.0280
Earnings date23 July 2024 - 28 July 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • PR Newswire

    Further CYP-001 GvHD Clinical Data Published in Nature Medicine

    Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the publication of two-year follow-up data of CYP-001 in patients with steroid-resistant acute graft versus host disease (SR-aGvHD) in the prestigious peer-reviewed journal Nature Medicine.

  • PR Newswire

    Patient Enrolment Completed in CYP-006TK Diabetic Foot Ulcer Clinical Trial

    Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the completion of patient enrolment in its Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers (DFU).

  • PR Newswire

    First Patient Treated in Phase 2 GvHD Trial

    Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, confirms that the first patient has been enrolled and treated in its Phase 2 clinical trial of CYP-001 in high-risk acute graft versus host disease (aGvHD).